（股份代號：1833） PING AN HEALTHCARE AND TECHNOLOGY COMPANY LIMITED 平安健康醫療科技有限公司 香港交易及結算所有限公司及香港聯合交易所有限公司對本通告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本通告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 （於開曼群島註冊成立之有限公司） 郭曉濤先生 主席 中國，上海 二零二六年三月二日 於本通告日期，董事會由執行董事何明科先生及臧珞琦女士；非執行董事郭曉濤 先生、付欣女士、蔡方方女士及朱梓陽先生；及獨立非執行董事湯雲為先生、郭 田勇先生及周永健博士組成。 董事會會議通告 平安健康醫療科技有限公司（「本公司」及其附屬公司「本集團」）董事（「董事」）會 （「董事會」）謹此宣佈，董事會會議將於二零二六年三月二十四日（星期二）舉行， 以審議及批准，其中包括，本集團截至二零二五年十二月三十一日止之全年業績 及其發佈以及考慮派發末期股息（如有）之建議。 承董事會命 平安健康醫療科技有限公司 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年2月28日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 平安健康醫療科技有限公司 呈交日期: 2026年3月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01833 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | USD | | 0.000005 | USD | | 50,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 10,000,000,000 | USD | | 0.000005 | USD | | 50,000 | 本月底法定/ ...

证券之星消息，2月27日南向资金增持64.82万股平安好医生（01833.HK）。近5个交易日中，获南向资 金增持的有4天，累计净增持259.18万股。近20个交易日中，获南向资金增持的有14天，累计净增持 1193.24万股。截至目前，南向资金持有平安好医生（01833.HK）4.87亿股，占公司已发行普通股的 22.53%。 平安健康医疗科技有限公司是一家通过移动平台和线下资源从事提供医疗及健康服务的公司。该公司通 过两个分部开展其业务。医疗服务分部主要从事在线咨询、转诊及预约挂号、住院安排、疾病诊疗及相 关药品、医疗器械销售。健康服务分部提供多种整合医疗健康机构服务的标准化健康服务包，以满足用 户健康相关需要，覆盖体检、养老、齿科、抗衰、泛健康等多品类及服务形态。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 ...

[Table_Page] 跟踪研究|软件与服务 证券研究报告 [Table_Title] 【广发医药&海外】平安好医生（01833.HK） 前瞻：预计收入稳健增长，利润率继续提升 [Table_Summary] 核心观点： | [Table_Invest] 公司评级 | 买入 | | --- | --- | | 当前价格 | 13.34 港元 | | 合理价值 | 19.65 港元 | | 前次评级 | 买入 | | 报告日期 | 2026-02-25 | [Table_PicQuote] 相对市场表现 -10% 46% 103% 159% 216% 272% 02/25 04/25 06/25 08/25 10/25 12/25 02/26 平安好医生 恒生指数 | [分析师： Table_Author]杨琳琳 | | | --- | --- | | | SAC 执证号：S0260514050004 | | SFC CE No. BNC117 | | | 0755-23480370 | | | yll@gf.com.cn | | | 分析师： | 罗佳荣 | | | SAC 执证号：S02605160900 ...

平安健康医疗科技有限公司是一家通过移动平台和线下资源从事提供医疗及健康服务的公司。该公司通 过两个分部开展其业务。医疗服务分部主要从事在线咨询、转诊及预约挂号、住院安排、疾病诊疗及相 关药品、医疗器械销售。健康服务分部提供多种整合医疗健康机构服务的标准化健康服务包，以满足用 户健康相关需要，覆盖体检、养老、齿科、抗衰、泛健康等多品类及服务形态。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 证券之星消息，2月23日南向资金增持69.2万股平安好医生（01833.HK）。近5个交易日中，获南向资金 增持的有4天，累计净增持674.9万股。近20个交易日中，获南向资金增持的有12天，累计净增持505.2万 股。截至目前，南向资金持有平安好医生（01833.HK）4.85亿股，占公司已发行普通股的22.45%。 ...

Group 1 - The mainland internet healthcare sector is entering a new phase driven by tech giants accelerating AI innovation and government policy support, such as the online initial diagnosis pilot program launched in Beijing [1] - Despite challenges in profitability, leading companies are leveraging AI ecosystems and innovative strategies for long-term sustainable growth [1] Group 2 - The company maintains a "Buy" rating for Alibaba Health (00241) with a target price of HKD 7.8, expecting a compound annual growth rate (CAGR) of 13% in revenue and 24% in adjusted net profit from FY2026 to FY2028, driven by growth in innovative drugs and healthcare products, deepening synergy with Alibaba Group (09988), and increasing AI application [1] - The company also favors Ping An Good Doctor (01833) with a "Buy" rating and a target price of HKD 20, anticipating a CAGR of 16% in revenue and 56% in adjusted net profit from FY2025 to FY2027, supported by deepening synergy with Ping An Insurance (02318) and ongoing AI empowerment [1] Group 3 - The company maintains an "Overweight" rating for the mainland healthcare sector, preferring leading innovative pharmaceutical companies and contract research, development, and manufacturing organizations (CRDMOs) [2] - The company is optimistic about internet healthcare firms that effectively utilize real-world data to optimize AI algorithms and enhance service quality [2] - Preferred stocks include BeiGene (06160), Innovent Biologics (01801), Hansoh Pharmaceutical (03692), China Biologic Products (01177), Hutchison China MediTech (00013), WuXi Biologics (02269), WuXi AppTec (02359), and Alibaba Health [2]

Group 1 - The mainland internet healthcare sector is entering a new phase driven by tech giants accelerating AI innovation and government policy support, such as the online initial diagnosis pilot program launched in Beijing [1] - Despite challenges in profitability, leading companies are leveraging AI ecosystems and innovative strategies for long-term sustainable growth [1] - Alibaba Health (00241) is favored with a "Buy" rating and a target price of HKD 7.8, with expected revenue and adjusted net profit CAGR of 13% and 24% from FY2026 to FY2028, driven by innovative drugs, healthcare product growth, and deepening synergies with Alibaba [1] Group 2 - Ping An Good Doctor (01833) is also favored with a "Buy" rating and a target price of HKD 20, with expected revenue and adjusted net profit CAGR of 16% and 56% from FY2025 to FY2027, supported by synergies with Ping An (02318) and ongoing AI empowerment [1] - The firm maintains an "Overweight" rating on the mainland healthcare sector, preferring leading innovative pharmaceutical companies and contract research, development, and manufacturing organizations (CRDMOs) [2] - Companies that effectively utilize real-world data to optimize AI algorithms and enhance service quality in internet healthcare are also favored, with preferred stocks including BeiGene (06160), Innovent Biologics (01801), Hansoh Pharmaceutical (03692), China Biologic Products (01177), Hutchison China MediTech (00013), WuXi Biologics (02269), WuXi AppTec (02359), and Alibaba Health [2]

Group 1 - The core viewpoint of the article highlights that southbound funds have increased their holdings in Ping An Good Doctor (01833.HK) by 112,100 shares on February 13, with a total net increase of 8.6263 million shares over the last five trading days [1] - Over the past 20 trading days, southbound funds have increased their holdings on 12 occasions, resulting in a cumulative net increase of 3.3276 million shares [1] - As of now, southbound funds hold 485 million shares of Ping An Good Doctor, accounting for 22.42% of the company's total issued ordinary shares [1] Group 2 - Ping An Health Medical Technology Co., Ltd. operates in the healthcare sector, providing medical and health services through mobile platforms and offline resources [1] - The company conducts its business through two segments: the medical services segment, which includes online consultations, referrals, appointment scheduling, hospitalization arrangements, disease diagnosis, and related sales of drugs and medical devices [1] - The health services segment offers a variety of standardized health service packages that integrate services from medical health institutions, addressing user health needs across multiple categories such as physical examinations, elderly care, dental services, anti-aging, and general health [1]

Core Viewpoint - Southbound funds have significantly increased their holdings in Ping An Good Doctor (01833.HK), indicating growing investor confidence in the company [1] Group 1: Southbound Fund Activity - On February 12, southbound funds increased their holdings by 3.9798 million shares of Ping An Good Doctor [1] - Over the past five trading days, there have been five days of net increases, totaling 9.0687 million shares [1] - In the last 20 trading days, there were 11 days of net increases, amounting to 2.2241 million shares [1] - Currently, southbound funds hold 485 million shares of Ping An Good Doctor, representing 22.42% of the company's total issued ordinary shares [1] Group 2: Company Overview - Ping An Good Doctor is engaged in providing medical and health services through mobile platforms and offline resources [1] - The company operates through two segments: the medical services segment, which includes online consultations, referrals, appointment scheduling, hospitalization arrangements, disease diagnosis, and related sales of pharmaceuticals and medical devices [1] - The health services segment offers standardized health service packages that integrate various medical health institution services to meet users' health-related needs, covering categories such as physical examinations, elderly care, dental services, anti-aging, and general health [1]

Group 1 - Ping An Good Doctor's stock closed at HKD 13.86, with a decline of 2.463% [1] - The company announced a change in leadership, with Li Dou resigning as Chairman, Executive Director, and CEO effective October 7, 2025 [1] - Guo Xiaotao will be appointed as Chairman, and He Mingke will become the CEO and Executive Director on the same date [1] Group 2 - On October 6, 2025, the stock price was HKD 17.86, reflecting a cumulative decline of 22.396% over the past four months [2] - The company's market value has decreased by HKD 8.6456 billion during this period [2]